Boehringer, Epizyme to develop small molecules against epigenetic cancer targets

By Alicia Parker | Nov 16, 2018 | 7:27 PM GMT

Boehringer Ingelheim GmbH (Ingelheim, Germany) partnered with Epizyme Inc. (NASDAQ:EPZM) to develop small molecule inhibitors of two undisclosed epigenetic cancer